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Abstract
Background: VA7 is a neurotropic alphavirus vector based on an attenuated strain of Semliki Forest virus. We have
previously shown that VA7 exhibits oncolytic activity against human melanoma xenografts in immunodeficient mice. The
purpose of this study was to determine if intravenously administered VA7 would be effective against human glioma.
Methodology/Principal Findings: In vitro, U87, U251, and A172 human glioma cells were infected and killed by VA7-EGFP.
In vivo, antiglioma activity of VA7 was tested in Balb/c nude mice using U87 cells stably expressing firefly luciferase in
subcutaneous and orthotopic tumor models. Intravenously administered VA7-EGFP completely eradicated 100% of small
and 50% of large subcutaneous U87Fluc tumors. A single intravenous injection of either VA7-EGFP or VA7 expressing Renilla
luciferase (VA7-Rluc) into mice bearing orthotopic U87Fluc tumors caused a complete quenching of intracranial firefly
bioluminescence and long-term survival in total 16 of 17 animals. In tumor-bearing mice injected with VA7-Rluc, transient
intracranial and peripheral Renilla bioluminescence was observed. Virus was well tolerated and no damage to heart, liver,
spleen, or brain was observed upon pathological assessment at three and ninety days post injection, despite detectable
virus titers in these organs during the earlier time point.
Conclusion: VA7 vector is apathogenic and can enter and destroy brain tumors in nude mice when administered
systemically. This study warrants further elucidation of the mechanism of tumor destruction and attenuation of the VA7
virus.
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Introduction
During the past decades malignant gliomas have presented with
an insurmountable obstacle in cancer treatment. While recent
results of a multi-center phase III clinical trial combining
radiotherapy (RT) with the DNA-alkylating agent temozolomide
(TMZ) have marked a true paradigm shift in treatment of
glioblastoma multiforme (GBM) [1], the most common type of
malignant glioma, patients rarely live beyond two years after
diagnosis and there are no cures. Radical surgery can alleviate the
effects of excess tumor burden and prolong meaningful life-span,
but remains palliative only [2].
One of the biggest reasons for the grim prognosis is the highly
invasive nature of gliomas. Glioma cells can migrate long distances
in the brain parenchyma and establish satellite lesions even in the
contralateral hemisphere [3]. Other reasons for treatment failure
are the vast genotypic and phenotypic heterogeneity of malignant
gliomas, limiting the effectiveness of any single therapeutic on a
population-wide scale, and the presence of tumorigenic cells
capable of both resisting conventional therapies as well as escaping
immune surveillance [4]. Recently, tumor-initiating cells (TICs)
were indentified in malignant gliomas [5]. These cells were later
shown to be resistant to ionizing radiation which could well
explain why radiation therapy fails to kill malignant gliomas [6].
Oncolytic viruses hold great promise as glioma-killing agents.
Reovirus [7], Newcastle disease virus (NDV) [8], Herpes simplex
virus-1 (HSV-1) [9,10], adenovirus [11], vesicular stomatitis virus
(VSV) [12], measles virus [13], myxoma virus [14], poliovirus [15]
and vaccinia virus [16] have emerged as potential vehicles to
combat malignant glioma and have shown oncolytic activity
against human glioma xenografts. However, while oncolytic
viruses must be able to kill cancer cells, they should leave normal
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[17] and vaccinia virus [18] have been engineered to selectively
replicate only in tumor cells. Other oncolytic viruses including
reovirus, measles virus, VSV and NDV, seem to have an inherent
capability to specifically replicate only in tumor cells, leaving
normal cells largely unaffected. The tumor permissiveness of viral
replication is often due to defects in the immunological/antiviral
status of the tumor cells. Defects in the interferon response of
tumor cells seem to explain the tumor-specificity of VSV [19] and
NDV [20]. Reovirus replication, on the other hand, is restricted to
cells with activated Ras signaling pathway [21].
Semliki Forest virus (SFV) is an enveloped, positive stranded
RNA virus of the family Togaviridae [22]. The natural hosts of SFV
are small rodents and birds while mosquitoes are the usual vector.
Human infections are also common and in certain parts of Africa
up to 40% of the population has been shown to be seropositive
[23–25]. Semliki Forest virus infection does not associate with any
disease in humans but it may cause mild symptoms such as
headache, fever and rash [23]. Several different strains of SFV
exist, some of which are highly virulent for laboratory mice, while
others are virulent only for neonatal mice. The A7(74) strain of
SFV is a naturally attenuated strain [26–28] which, like the
virulent wild type strains L10 and SFV4, is neurotropic, infecting
both neurons and glial cells, but unlike the these strains which
induce fatal encephalitis in mice irrespective of their age, A7(74) is
lethal only for newborn mice [26,29]. In mice older than two
weeks, replication of A7(74) in neurons is severely restricted and
the mice survive the infection without neurological sequealae [29].
The mechanism of neuronal restriction of replication is yet
unknown but has been shown to be independent of type I
interferon signaling [30].
We have constructed a replication-competent expression vector
VA7-EGFP based on the A7(74) virus [31]. VA7-EGFP has been
shown to replicate in and kill a number of cultured tumor cells
similar to SFV4 and to be able to deliver therapeutic genes into the
CNS of diseased mice upon intraperitoneal injection [31]. In a
recent report, we have described the oncolytic potential of VA7-
EGFP against human melanoma xenografts in severe combined
immunodeficient (SCID) mice [32].
Given the oncolytic potential and CNS tropism of VA7 upon
peripheral administration, it was of interest to investigate whether
VA7 would be able to inhibit the growth of human glioma
xenografts implanted either subcutaneously or orthotopically in
nude mice. In the present report we show that intravenously
administered VA7 virus effectively eradicated both subcutaneous
and orthotopic U87MG tumor xenografts in nude Balb/c mice.
Besides initial transient viremia none of the mice displayed any
neurological symptoms or signs of pathology.
Results
VA7-EGFP–Induced Oncolysis in Glioma Cell Lines
U87, U251 and A172 cell lines were all infected by VA7-EGFP
(Figure 1B) but the rate of spread was different in each one. Cell
viability assay showed that U87 cells were killed within 96 hours at
very low MOI values with 42% of the cells being alive at MOI
0.001 and at MOI 0.1 only 1.8% of the cells were viable at this
time point (Figure 1A). U251 cells required a 100-fold higher viral
dose to achieve a similar degree of cell death with 53.4% of the
cells alive at MOI 0.1 and 4.1% alive at MOI 10. The sensitivity of
A172 cells to VA7-EGFP fell between the other two glioma cell
lines with 36.4% of the cells being viable at MOI 0.01 (Figure 1A).
Viral replication in the infected cells was confirmed by Western
blot analysis of viral structural proteins. In all cell lines, the 30 kDa
capsid, 50 kDa E1 and E2 proteins as well as the p62 precursor
protein were abundantly expressed, confirming productive infec-
tion (Figure 1C).
Characterization of Luciferase Expressing U87 Cells
U87 cells transduced with the lentiviral vector WPTFluc at MOI
1, 5, 25 and 50 exhibited Fluc activity which increased linearly with
increasing virusdose (Figure S1A). Fluc expression didnot affectcell
proliferation as compared to non-transduced control cells (Figure
S1B) and we chose to use U87 cells that had been transduced at
MOI 25 for subsequent studies. Fluc expression did not change the
sensitivityofthe U87FluccellstoVA7-EGFP–induced cellkillingas
compared to parental U87 cells (Figure S1C). Flow cytometry
analysis showed that at least 94% of the cells in U87Fluc cell
population were Fluc positive (Figure S1D).
Oncolytic Efficacy of VA7-EGFP in Subcutaneous Nude
Mouse Model
When the subcutaneous tumors had reached average sizes of
either 96.5 mm
3 (small) or 442 mm
3 (large), the mice were injected
intravenously in the tail vein with 10
6 PFU of VA7-EGFP. Median
survival of mice treated with PBS was 26 days (95% CL=25 days
to 28 days) at which time point the tumor size had reached
1040 mm
3 (95% CL=732 mm
3 to 1344 mm
3) (Figure 2A, B) and
the animals were sacrificed. For the small tumors, a single injection
of the virus led to complete and lasting tumor eradication in all of
the 5 treated animals over a 4-month follow-up period (Figure 2A).
A single intravenous injection of the virus in mice harboring large
tumors produced one full cure out of six with a median survival
time of 49 days (95% CL=41 days to 53 days) and a significant
increase in survival compared to the PBS-treated group (log-rank
test, P,0.01) (Figure 2A,B). Three weekly injections with VA7-
EGFP yielded three out of six cures (median survival not reached),
also with a significant increase in survival (log-rank test, P,0.005)
(Figure 2A,B). VA7-EGFP did not induce any neurological or
other symptoms in the treated mice, and no effect on animal
weight was observed (Figure S2).
Histological examination of tumors isolated 7 days after a single
injection with VA7-EGFP showed wide-spread necrosis with only
very few regions of Fluc positive live tumor cells which were
located next to an SFV-positive region implying that the viral
infection was still proceeding (Figure 3A). While those xenografts
that regrew after three weekly doses of virus were large at study
end point, Fluc positive cells were still restricted to the periphery of
the tumors (Figure 3B). In parallel HE-stained sections the bulk of
the tumors appeared necrotic (Figure 3B, insert). In contrast,
tumors isolated from untreated animals showed widespread
distribution of live, Fluc positive tumor cells with necrotic areas
detected mainly in the very core of the tumor sample (Figure 3C).
Assessment of the Presence of Virus-Resistant Cells in
Regrowing Tumors
In order to study whether tumor regrowth after initial regression
was due to emergence of virus-resistant cells, we established several
explant cell lines from treated regrowing tumors as well as PBS-
treated tumors, and infected them with different concentrations of
stock virus. All explant cell lines were Fluc positive as judged from
staining with anti-luciferase antibody (Figure S3A). Despite
quantitative differences in the sensitivity to virus-induced cell
killing between the explanted cells and the parental U87Fluc cells
at MOI values between 0.001 and 0.01, all explant cell lines from
treated-tumors were more sensitive to VA7-EGFP than cell lines
isolated from PBS-treated tumors (Figures S3B). Hence, the failure
Antiglioma Activity of SFV
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due to virus-resistant glioma cells as observed previously using
VA7-EGFP in a human melanoma model [32].
Oncolytic Efficacy of VA7-EGFP in Orthotopic Nude
Mouse Model
Mice with established intracranial tumors assessed by IVIS were
either given an intravenous injection of PBS (CTRL) or treated with
a single intravenousinjectionof1610
6 PFUof VA7-EGFP. Median
survivalofanimalstreated withPBSwas36days(95%CL=26days
to 42 days) at which time the Fluc end point value of 10
9 photons/
sec/cm
2/steradianwas reached (approximately one week beforethe
onset of neurological symptoms). In the VA7-EGFP-treated mice,
Fluc signal was completely quenched within 6 days after virus
injection, remaining undetectable in all 5 mice during the 100-day
follow-up (Figure 4). Neither weight loss nor neurological symptoms
were observed, and we also did not find any persistent virus in the
CNS of these animals by titration (data not shown).
Replication of VA7-Rluc in Naı ¨ve and Tumor-Bearing Mice
To study the virus biodistribution we infected 11 naı ¨ve mice
with 1610
6 PFU of VA7-Rluc. The animals were sacrificed at
days 3, 6 and 9 post infection and brains, heart, liver and spleen
were removed for titration and histology. Virus was detected in all
analyzed organs at day 3 but exclusively in the brain at day 6. No
virus was recovered from any organ beyond this time point
(Table 1). Histological assessment of the organs at day 3 revealed
no histopathological changes (Figure S7).
To relate the viral titers to ectopic expression of Renilla luciferase
we injected 6 mice bearing intracranial tumors with VA7-Rluc.
We used ViviRen substrate, shown to give bioluminescence signals
up to three times higher than coelenterazine, the natural substrate
of Rluc [33]. Between 16 and 40 hours post injection, five animals
exhibited Rluc which co-localized with tumor-derived Fluc (for
complete time course see Figure S4). In four animals transient
Rluc expression could be observed in peripheral organs
(Figure 5A). Tumor signal was undetectable in all mice by 4 days
post injection, but reappeared in one mouse (mouse 1) at day 24,
only to regress again and remain absent at the final measurement
101 days post injection (Figure S4). All the animals treated
intravenously with either VA7-EGFP or VA7-Rluc virus were
alive at 120 days post implantation (Figure 5B), and all except one
(mouse 5) scored negative for tumor signal. Post mortem histology
of the brain of this Fluc-positive animal revealed one larger cluster
Figure 1. VA7-EGFP kills glioma cells in vitro. (A) Dose-dependent killing by VA7-EGFP of U87, U251 and A172 glioma cells in culture. Glioma
cells were seeded in a 96-well plate and VA7-EGFP at MOI ranging from 10
25 to 10
1 was added 16 hours later. Cell viability was assessed 96 hours
later using calcein AM as indicator of cell membrane integrity. The mean values and standard deviations are shown. (B) Photograph of the cells at
96 hours post infection with VA7-EGFP at MOI 0.1. Fluorescence channel for VA7-EGFP shows GFP-positive cells indicative of active virus replication.
(C) Western blot of VA7 structural protein expression in untreated and VA7-EGFP -infected cells 18 hours post infection. Equal number of cells were
infected at MOI 1 and collected for Western analysis 18 hours later. In all cell lines the 30 kDa capsid, the E1 and E2 50 kDa proteins and the E2
precursor p62 were abundantly expressed.
doi:10.1371/journal.pone.0008603.g001
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wound healing process was also apparent, although at a relatively
long distance from the residual tumors (Figure 5C). No Fluc
positive cells were found in the brains of the other 5 animals and in
addition to mouse 5, signs of tissue trauma were evident also in the
brain of mouse 6 (Figure S5). In both cases, these regions were
most likely the original tumor sites. We also examined the brains of
all tumor-bearing mice which had received VA7-Rluc for the
presence of SFV antigen, but no persistent virus could be detected
(result shown for mouse 5 in Figure 5C).
We repeated the survival experiment with similar results. Only
one out of 6 U87Fluc implanted and VA7Rluc –treated mice
Figure 2. Effect of intravenous injection of VA7-EGFP on the growth of subcutaneous U87Fluc tumor xenografts. (A) U87Fluc cells
(5610
6) were implanted subcutaneously in nude mice and when the tumors had grown to an average size of 100 mm
3, the animals were given a
single intravenous injection of either PBS or 1610
6 PFU of VA7-EGFP. In another two groups, the tumors were allowed to grow until they reached an
average size of 450 mm
3 and the animals were given either a single intravenous injection of 1610
6 PFU of VA7-EGFP or three injections of the virus at
7-day intervals, each 1610
6 PFU. (B) Kaplan-Meier survival analysis of mice with subcutaneous U87Fluc xenografts and treated with either PBS or
intravenous injections of VA7-EGFP.
doi:10.1371/journal.pone.0008603.g002
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animals survived 90 days after virus injection and histological
assessment revealed no pathological changes in the organs studied
(Fig. S7). Also, we were unable to detect virus in the treated mice
at day 90 (Table 1). In contrast, immunohistochemical analysis of
three tumor-bearing animals sampled at day 3 post virus injection
revealed disseminated virus antigen in the intracranial tumors thus
confirming productive infection of glioma xenografts (Fig. 6).
Discussion
In the present paper we describe the oncolytic potential of the
SFV vector VA7 in a nude mouse model of human glioma. The
initial results that small subcutaneous tumors were completely
eradicated by a single injection of VA7-EGFP were promising, but
regrowth after initial regression of larger tumors was suggestive of
emerging resistance, as seen in a human melanoma model [32].
However, as the isolated explant cultures could be killed by VA7-
EGFP, mechanisms other than resistance to VA7 are responsible
for the failure to achieve complete eradication of large tumors.
The observation that larger tumors do not respond as well as
smaller tumors to oncolytic virus is not new [34]. For example,
subcutaneous rhabdomyosarcoma [35], human lymphoma xeno-
grafts [36] and orthotopic gliomas [37] showed reduced response
as tumor size increased. Apart from tumor-related barriers, such as
connective tissue and increased interstitial pressure, the innate
immune system is known to restrict virus spread and to cause
premature virus clearance [34,38]. While SFV establishes a
viremia that lasts up to 4 days, even nude mice clear the virus
with kinetics similar to immunocompetent animals, mediated by
serum IgM [39]. Because attenuated SFV is cleared at a slower
rate from the brain [29] it may be particularly well suited to target
intracranial tumors.
A major reason for glioma recurrence is the invasion of the
healthy brain parenchyma [40]. Although the U87 nude mouse
model is not generally considered invasive, sporadic tumor cells
have been detected outside the main tumor mass and the model
does recapitulate some of the other characteristics of human
malignant glioma [12,41]. Also, the gene expression of U87 and
U251 cells change towards a common profile when they are
implanted orthotopically rather than subcutaneously [42], and
only in orthotopically implanted U87 xenografts can purported
CD133-positive brain tumor stem cells be detected [43]. It was
therefore encouraging to observe that a single intravenous
Figure 3. Histological analysis of subcutaneous U87Fluc tumor xenografts. Anti-SFV immunostaining, anti-luciferase staining and H&E
staining, respectively, of parallel sections of residual tumor tissue in a mouse 7 days after injection with a single intravenous dose of 1610
6 PFU of
VA7-EGFP (A) or 21 days after the third injection of VA7-EGFP (B) (original magnification6200, insert610). (C) Similar staining of a xenograft from a
PBS-treated tumor-bearing mouse. n=necrotic tissue, l=live cells. Bar=5 mm.
doi:10.1371/journal.pone.0008603.g003
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majority of the animals harboring orthotopic xenografts. Only one
animal out of 17 intravenously-treated mice relapsed and only in
one mouse residual tumor cells could be detected at the study end
point. In comparison, intratumoral administration of reovirus [7],
myxomavirus [14], intergeneric poliovirus [15] or chimeric HSV-1
[44] has produced long term, tumor-free survivors in the range of
75 to 100%, but where studied, peripheral administration has
produced none. Mutant VSV was recently shown to retard the
growth of U87 orthotopic tumor xenografts after intravenous
administration but all the animals eventually died of recurrent
tumors [12]. This was not likely due to poor virus penetration into
the tumors, as in another study systemic administration of VSV
effectively induced apoptosis in virtually all cells of orthotopic
glioma xenografts [45].
It remains unclear whether the remaining Fluc-positive cells in
the sole mouse displaying Fluc-signal at study end point (Figure
S4, mouse 5) could have formed a viable tumor, as another tumor-
bearing animal treated with VA7-Rluc and apparently tumor-free
(Figure S4, mouse 1) presented later with recurrent Fluc signal
that, however, eventually cleared and no remaining tumor cells
were seen in the brain at the end of the study. Although we do not
exclude the possibility that persisting virus in the brain re-infected
the residual cells in this mouse, in contrast to previous reports
using SFV A7(74) [29,39]. We could not find any evidence of VA7
virus persistence in the brains of the nude mice. This discrepancy
might be explained by genetic differences between the cloned VA7
virus and the parental virus [28,31].
A potential limitation of using systemic delivery of oncolytic
viruses is replication outside the target tissue. In the present study,
Renilla bioluminescence indicative of VA7 replication could be
detected outside tumor tissue indicating that VA7 does not show
strict tumor specificity which is not unexpected. This appears to be
the case even for SFV replicons [46]. We could not detect any
Figure 4. Effect of a single intravenous injection of VA7-EGFP on the growth of orthotopic U87Fluc xenografts. U87Fluc cells (2610
5)
were implanted stereotactically in nude mice. Tumor growth was monitored by measuring the light produced by the tumor cells with a cooled CCD
camera after the animals had been injected with luciferin. Sixteen days post tumor implantation 5 mice harboring intracranial tumors received a
single i.v. injection of 1610
6 PFU of VA7-EGFP. Tumor signal was extinguished within 6 days and remained below detection limit until the end of the
study. A PBS-treated mouse is provided as comparison (CTRL).
doi:10.1371/journal.pone.0008603.g004
Table 1. Viral titers in organs from VA7-Rluc–treated nude mice.
Day 3 (n=4) Day 6 (n=4) Day 9 (n=3) Day 90 (n=5)
Brain 5.8610
2 (40–1.2610
3)2 610
4 (8610
3–3610
4)N D N D
Heart 1610
4 (1610
4–1.1610
4)N D N D N D
Liver 6.3610
3 (9610
2–1.9610
4)N D N D N D
Spleen 1.9610
4 (4.8610
3–4.7610
4)N D N D N D
Viral titer (PFU/g tissue).
ND=not detected.
Data from mice sampled at day 90 are from in vivo experiment shown in Figure S6.
doi:10.1371/journal.pone.0008603.t001
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suggests that the sensitivity of Rluc imaging is not high enough to
detect such low levels of virus as present in the organs of naı ¨ve
mice. Plaque assay, however, revealed transient presence of virus
in all analyzed organs but none of the treated animals displayed
any neurological symptoms of infection and no histopathological
changes were observed (Figure S7) showing that VA7 virus is a safe
vector in adult hosts. This is corroborated by numerous studies
both in animals and CNS model systems using parental SFV
A7(74) [26,28,29,39].
Figure 5. A single intravenous injection of VA7-Rluc has potent antiglioma effect in nude mice bearing orthotopic U87Fluc tumors.
(A) Orthotopic U87Fluc xenografts were established in Balb/c nude mice by stereotactic injections of the tumor cells. When the firefly
bioluminescence from the tumor xenografts reached appropriate levels the animals were given an intravenous injection of 1610
6 PFU of VA7-Rluc.
After 24 hours, the animals were injected intravenously with ViviRen substrate and the light produced by the VA7Rluc vector was monitored by a
cooled CCD camera. Transient virus replication (Rluc) could be detected in the brain, co-localizing with the tumor (Fluc), as well as in the periphery.
Even tumors close to endpoint were fully eradicated. Virus signals can be compared with each other but not with tumor signal due to different
intensity scale. (B) Long-term survival of mice in Figure 4 and Figure 5A. None of the animals treated intravenously with either VA7-EGFP or VA7-Rluc
reached the end point bioluminescence value. The median survival of PBS-treated (CTRL) mice was 36 days (95% CL=26 days to 42 days) and all
differences to this group were highly significant (log-rank test, P,0.0001). (C) Sagittal section of the brain of mouse 5 stained against Fluc (top left).
This mouse was given a single intravenous dose of 1610
6 PFU of VA7-Rluc and was the only one in the group of intravenously -treated mice that
produced an intracranial Fluc IVIS signal at the final measurement of the experiment. Top right,2 0 6magnification of box 1 showing a Fluc-positive
cell cluster. Bottom left,1 0 6 magnification of box 1 showing anti-SFV immunostaining of parallel brain section from the same mouse. No SFV
immunoreactivity could be detected anywhere in the brain of this or any other i.v. treated mouse. Bottom right,1 0 6magnification of the region in
box 2 from a parallel section stained with H&E. The increased cellular density surrounding the blood vessel in the picture is indicative of regenerative
activity. This region was possibly the site of the original tumor before destruction by the VA7-Rluc virus.
doi:10.1371/journal.pone.0008603.g005
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vector VA7 based on attenuated SFV effectively infects and kills
human glioma tumors in nude mice while leaving healthy brain
t i s s u eu n h a r m e d .W ew a n tt os t r e ss, however, that because of
the extreme susceptibility to VA7 of U87 cells, our experiments
may give an overestimation of the oncolytic efficacy of this virus
and should therefore be considered the best case scenario. Thus,
this work is the prelude to studies addressing the oncolytic
capacity of attenuated SFV in the presence of an intact immune
system. If the results of this study can be validated in
immunocompetent models, the possibility to administer the
virus systemically and its natural capacity to pass the blood-
brain-barrier are attractive features that may prove beneficial in
clinical settings.
Materials and Methods
Ethics Statement
All animal work has been conducted according to relevant
national and international guidelines. Approval has been obtained
from the Finnish National Review Board for Animal Experimen-
tation.
Cell Lines
U87MG and A172 human glioma cell lines were obtained from
the American Type Culture Collection (ATCC). U251 human
glioma cells were obtained from Dr. J. Wahlfors (A.I. Virtanen
Institute, Kuopio, Finland). The cells were cultured in Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum at 37uC
in 5% CO2. U87Fluc cells were established by lentiviral
transduction using WPTFluc, constructed by replacing the GFP
gene in WPTGFP (from Dr. D. Trono) with the luciferase gene
from pMIR-REPORT
TM plasmid (Ambion Inc., TX, USA).
Construction and Production of VA7 Vectors
Construction and production of VA7-EGFP has been described
[31]. VA7-Rluc was constructed by cutting the gene encoding
Renilla luciferase from pRL-Null vector (Promega, Madison, WI,
USA) with XbaI and NheI and blunt-cloning it into the pSTBlue-1
vector (Novagen, Madison, WI, USA), from which it was cut out
using BamHI and AvrII and then inserted into the VA7 vector cut
with the same enzymes.
Cell Viability Assay
Glioma cells were plated at 3610
3 cells per well on a 96-well
plate. VA7-EGFP at MOI 10
25–10
1 was added 16 hours later
in a volume of 10 ml and the cells were incubated for 96 hours.
Calcein AM was added to a final concentration of 1 mMa n dt h e
cells were incubated for 12 minutes at 37uC, after which the
w e l l sw e r er i n s e do n c ew ith PBS and finally, 50 mlo fP B Sw a s
pipetted to each well and fluorescence was measured with
Victor 1420 Multilabel Counter (Perkin-Elmer Wallac, Turku,
Finland).
Immunodetection of VA7-EGFP Structural Proteins
Glioma cells were seeded at 2610
5 cells/well on a 6-well plate.
Twenty hours later VA7-EGFP was added at an MOI of 1. After
18 hours the medium was removed and the samples were
processed for Western analysis as described in [28].
Virus Titration
MBA-13 cells were seeded on 6-well plates at 3610
5/well.
Tissue homogenates were added 24 hours later and incubation
was continued for one hour. The medium was then replaced with
a medium containing 0.5% FCS and 0.4% SeaPlaque agarose.
After 48 hours the agarose was removed and the cell monolayers
fixed and stained with crystal violet solution (0.2% crystal violet w/
v, 5% formaldehyde and 1% ethanol).
Animals
Seven-to-eight-week-old female Balb/cOlaHsd Foxn12/2
mice were purchased from Harlan Laboratories (Allerod, Den-
mark) and housed in filter cages in groups of 4 mice per cage.
Animal experiments were conducted in Turku and Kuopio,
Finland, under experimental protocols approved by the Finnish
National Review Board for Animal Experimentation.
Evaluation of VA7-EGFP Anti-Glioma Activity in
Subcutaneous Tumor Model
To induce subcutaneous tumors, 5610
6 U87Fluc cells in 100 ml
of PBS were injected into the right flanks of nude Balb/c mice.
Tumor length and width were measured every third day with a
caliper and the tumor volumes were calculated from the equation
(length6width
2)/2. When the tumors reached ,100 mm
3, four
mice received a single intravenous injection of PBS (control). A
group of 5 mice received a single intravenous injection of 1610
6
PFU of VA7-EGFP. The rest of the animals were left untreated
until the average tumor size was 450 mm
3, at which point a group
of 6 mice received a single intravenous injection of 1610
6 PFU
VA7-EGFP while another group of 6 mice received three
intravenous injections of VA7-EGFP, each 1610
6 PFU, at 7-day
intervals. Additional 7 mice with tumor sizes averaging 450 mm
3
received either a single or three injections of VA7-EGFP and were
used for histological studies. Animals were killed with CO2 when
the tumor size reached 800 mm
3.
Figure 6. Immunohistochemical analysis of VA7 replication in
intracranial U87Fluc xenografts. U87Fluc cells were implanted in
the striatum Balb/c nude mice and tumor growth was monitored by
magnetic resonance imaging. When tumors were visible mice were
injected with 1610
6 pfu of VA7-EGFP and sacrificed three days later.
Brains were removed and paraffin sections prepared. (A–D) Represen-
tative images of U87Fluc xenograft immunostained against Fluc (A,C)
and SFV antigen (B,D). (A,B) magnification, 627; (B,D) 3.76magnifica-
tion of boxed areas in (A,B).
doi:10.1371/journal.pone.0008603.g006
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U87Fluc cells were cultured as described above. Cells were
detached with trypsin/EDTA, spun down, washed with PBS and
suspended in PBS at 2610
5 cells/3 ml. Mice were anesthetized
with an intraperitoneal injection of ketamine (75 mg/kg) plus
medetomidine (1 mg/kg). The animals were placed on a
stereotactic apparatus (Stoelting, Wood Dale, IL, USA), the head
was cleaned with 70% isopropanol solution and an incision was
made along the midline. The skin was withdrawn to the sides and
a burr hole with a diameter of 0.5 mm was drilled 0.5 mm
anterior and 1.5 mm lateral to bregma. A 10 ml Hamilton syringe
with a 30 gauge needle was mounted on the stereotactic frame and
lowered to a depth of 3 mm at 1 mm/min. Two hundred
thousand cells in 3 ml PBS were injected at 1 ml/min. After the
injection was completed, the needle was kept in place for
additional two minutes and then slowly withdrawn. The skin folds
were closed with polyamide surgical thread and the animals were
aroused with an i.p. injection of atipamezole (Antisedan, 1 mg/
kg). Three weeks later the mice were imaged for intracranial Fluc
activity. Mice with intracranial bioluminescence were randomly
divided into three groups. A group of 6 mice was injected with
PBS while another group of 5 mice received a single intravenous
dose of 1610
6 pfu of VA7-EGFP. Using the PBS group, an IVIS
end point for sacrifice of the mice (1610
9 photons/sec/cm
2/
steradian) was set to roughly one week before the appearance of
clinical signs due to tumor burden.
VA7-Rluc Replication in Tumor-Bearing Nude Mice
U87FLuc tumor cells were implanted intracranially in 6 nude
mice as described above and imaged for the presence of
intracranial firefly bioluminescence 16 days later. Three biolumi-
nescence positive mice were injected intravenously with 1610
6
PFU of VA7-RLuc. The mice were imaged for Renilla biolumi-
nescence at 16, 24, 40 and 96 hours post injection. After the last
time point when Rluc signal had abated, the mice were imaged for
Fluc activity and followed regularly until the termination of the
study. Tumor signal in the remaining three tumor-bearing mice
was monitored regularly until close to the IVIS endpoint upon
which the mice received a single intravenous injection of 1610
6
pfu of VA7-Rluc and were imaged as above. The experiment was
repeated with 6 tumor-bearing mice which received a single
injection of VA7-Rluc but this time only firefly bioluminescence
was monitored.
In vivo Imaging
For detection of Fluc activity, mice were injected intraperito-
neally with 150 ml of beetle luciferin (Promega, Madison WI,
USA) at 2 mg/ml and anesthetized with a continuous 2.5%
isoflurane flow. Ten minutes later, the animals were moved into
IVIS 50 (Xenogen) apparatus chamber with ongoing anesthesia
and 30 second images were acquired. For detection of VA7-Rluc,
mice were injected intravenously with 100 mlof ViviRen substrate
(Promega) at 0.2 mg/ml in 0.1% bovine serum albumin-PBS
under continuous isoflurane anesthesia. Mice were imaged two
minutes after substrate injection using data acquisition time of
3m i n u t e s .
Histology
Mice were CO2 -euthanized and perfused intracardially with
PBS. Organs were removed, fixed in paraformaldehyde, embed-
ded in paraffin, sectioned and stained with hematoxylin and eosin,
rabbit anti-SFV antibody (1:3000) and polyclonal anti-luciferase
antibody (1:250, MBL Medical & Biological Laboratories Ltd,
Nagoya, Japan) as described [28].
Statistical Analyses
Survival curves were generated by the Kaplan – Meier method
and the log-rank test was used to compare groups. All reported P
values are two-sided and are considered to be statistically
significant at P,0.05.
Supporting Information
Figure S1 Characterization of Fluc expressing U87 glioma cells.
A) U87 cells were transduced with the lentiviral vector WPTFluc
at MOI 1 to 50 and the luciferase activities of the transduced cells
were determined. B) U87 cells expressing Fluc were seeded on a
96-well plate and proliferation of the cells was measured during a
5-day period using calcein AM probe as an indicator of viable
cells. Results are shown as the means and 95% confidence
intervals. C) Oncolytic activity of VA7-EGFP on the parental U87
cells and cells which had been transduced with WPTFluc at MOI
25 (U87Fluc25) was investigated. VA7-EGFP was added to cells at
MOI 1023 to 1. Cell viability was measured 96 hours later using
the calcein AM probe. The results are shown as the means and
95% confidence intervals. D) Flow cytometry analysis of U87 and
U87Fluc cells detected with anti-luciferase antibody and Alex-488
-coupled secondary antibody.
Found at: doi:10.1371/journal.pone.0008603.s001 (0.29 MB TIF)
Figure S2 Effect of intravenously administered VA7-EGFP on
the weight of nude mice. Balb/c nude mice received a single
intravenous injection of either PBS (n=3) or 161E6 PFU of VA7-
EGFP (n=3). The animals were weighed every 6th day during a
48-day period. During this time period no neurological symptoms
or other adverse effects in the virus-treated group was observed.
The results are shown as the means and 95% confidence intervals.
Found at: doi:10.1371/journal.pone.0008603.s002 (0.05 MB TIF)
Figure S3 Characterization of tumor cell explants from
subcutaneous U87Fluc tumors. A) Cell lines established from
subcutaneous U87Fluc tumors that had progressed after initial
response were grown on cover slips and stained with anti-luciferase
antibody followed by detection with Alexa 488-coupled secondary
antibody. Left, fluorescence; right, phase contrast photomicro-
graphs. B) Eight cell lines derived from 7 different subcutaneous
tumors, which had regrown after VA7-EGFP treatment, were
exposed to VA7-EGFP at increasing MOI. Also two cell lines
derived from tumors of two PBS-treated mice as well as the
parental cell line U87Fluc were exposed to the virus. Cell viability
was measured 96h later using calcein AM probe. Sensitivities for
VA7-EGFP-induced cell killing of the cells derived from VA7-
EGFP-treated tumors fell between those of U87Fluc cells and cells
derived from tumor of a PBS-treated mouse. Each data point is the
mean of 6 determinations and the error bars are not shown for the
sake of clarity.
Found at: doi:10.1371/journal.pone.0008603.s003 (2.49 MB TIF)
Figure S4 VA7-Rluc replication in U87Fluc tumor-bearing
mice. Orthotopic U87Fluc xenografts were established in nude
mice by stereotactic injections of the tumor cells. When the firefly
bioluminescence from the tumor xenografts reached appropriate
levels the animals were given an intravenous injection of 161E6
PFU of VA7 expressing Renilla luciferase. After either 16 or
24 hours the animals were injected intravenously with Viviren
substrate and the light produced by the VA7Rluc vector was
monitored by a cooled CCD camera. Transient virus replication
(Rluc) could be detected in the brain, co-localizing with the tumor
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with each other but not with tumor signal due to different intensity
scale. Tumor signal was extinguished within 4 days, irrespective of
the size of the tumor at the start of the treatment. In all but one
mouse (nr. 5), tumor signal remained below detection limit at the
end of the study. In another mouse (nr. 1), tumor regrowth
followed by remission could be detected after day 4 post injection.
Found at: doi:10.1371/journal.pone.0008603.s004 (4.04 MB TIF)
Figure S5 Hematoxylin and eosin staining of brain tissue of
VA7-Rluc-treated mice 120 days after U87Fluc tumor implanta-
tion. After the final in vivo imaging the mice shown in figure 5 were
intracardially perfused with PBS, the brains were removed and
fixed in formalin and embedded in paraffin. Sagittal sections were
prepared and stained with hematoxylin and eosin. For mouse 5,
which was the only Fluc positive animal at the final measurement,
a section taken 100 mm mediolateral from the one shown in
Figure 5 is presented here. Also in this section signs of tissue defects
are evident (boxed area) although no residual tumor cells can be
distinguished. A tissue trauma is also evident in the brain of mouse
6 (boxed area). This site is most likely the original tumor site but no
tumor cells can be detected in this section and nor were Fluc cells
detected in other sections from this animal either. For mice 5 and
6a1 3 6magnification of the trauma sites are shown on the right.
Bar=1.0 mm.
Found at: doi:10.1371/journal.pone.0008603.s005 (5.61 MB TIF)
Figure S6 Effect of a single injection of VA7-Rluc on the growth
of intracranial U87Fluc xenografts. U87Fluc cells were implanted
stereotactically in Balb/c nude mice and the tumor growth was
monitored by IVIS Imaging system. Eighteen days later the
animals were given a single injection of 161E6 pfu of VA7-Rluc or
PBS (controls). Of the virus-treated mice only one developed
tumor after initial tumor regression (mouse 1). Rest of the animals
stayed tumor-free for the rest of the follow-up period. Fluc
bioluminescence in PBS-treated mice reached end point level in
two weeks.
Found at: doi:10.1371/journal.pone.0008603.s006 (3.61 MB TIF)
Figure S7 Hematoxylin and eosin staining of organs from VA7-
treated mice. Left panel, Balb/c nude mice were injected with
161E6 PFU of VA7-Rluc and the animals were sacrificed at days
3, 6 and 9 after infection. Brain, heart, liver and spleen were
removed for titration and histological analysis. Representative
images of HE-stained organs from a mouse sampled at day 3 post
infection. Right panel, organs from the VA7-Rluc-treated mice
from the in vivo experiment shown in Figure S6 were removed at
the termination of the study and cut in half. One half was frozen in
liquid nitrogen for plaque assay and the other half was fixed in
paraformaldehyde and processed for hematoxylin and eosin
staining. Representative HE images from mouse 3 are shown.
Original magnifications: brain6100, heart, spleen and liver6200.
Found at: doi:10.1371/journal.pone.0008603.s007 (13.82 MB
TIF)
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